You are here

Microfluidic Dielectrophoretic Screening System

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W81XWH-10-C-0217
Agency Tracking Number: C101-107-0024
Amount: $69,994.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: CBD10-107
Solicitation Number: 2010.1
Solicitation Year: 2010
Award Year: 2010
Award Start Date (Proposal Award Date): 2010-05-17
Award End Date (Contract End Date): 2010-11-17
Small Business Information
Photonic Systems Division 20600 Gramercy Place, Bldg. 100
Torrance, CA 90501
United States
DUNS: 153865951
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 Gregory Zeltser
 Principal Scientist
 (310) 320-3088
Business Contact
 Gordon Drew
Title: Chief Financial Officer
Phone: (310) 320-3088
Research Institution

To address the U.S. Army/DTRA’s CBD program need for a robust screening process for use with large panels of enzymes to identify variants with higher affinity for organophosphorus (OP) substrates, Physical Optics Corporation (POC) proposes to develop a Microfluidic Dielectrophoretic Screening (MDS) system. This proposed system is based on the new design of a microfluidic mixer, enzymatic reactor, and readout unit that uses in-house developed mature components. The innovations in the MDS system will enable the completion of enzyme kinetic measurements in 15 minutes. Also, the MDS system requires nanogram quantities of an enzyme; and the microfluidic chip is self-contained, reusable, and sufficiently robust to withstand routine cleaning with highly basic and alcoholic solutions. As a result, this technology will provide the DoD with an improved capability to develop novel scavengers of OP nerve agents. In Phase I, POC will demonstrate the feasibility of the MDS system by developing a robust and high-throughput prototype capable of identifying enzyme variants with reduced KM values for OP compounds. In Phase II, POC plans to further develop, refine, and validate the MDS system, using nerve agent simulants followed by validation with OP nerve agents, at a testing facility approved for using these materials.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government